| 2022-03 | Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses | Kim, Jeongrae; Choi, Yongwhan; Yang, Suah; Lee, Jaewan; Choi, Jiwoong; Moon, Yujeong; Kim, Jinseong; Shim, Nayeon; Cho, Hanhee; Shim, Man Kyu; Jeon, Sangmin; Lim, Dong-Kwon; Yoon, Hong Yeol; Kim, Kwangmeyung |
| 2022-09 | Novel 2,6,9-Trisubstituted Purines as Potent CDK Inhibitors Alleviating Trastuzumab-Resistance of HER2-Positive Breast Cancers | Kuchukulla, Ratnakar Reddy; Hwang, Injeoung; Park, Sang Won; Moon, Sojeong; Kim, Suhn Hyung; Kim, Sumin; Chung, Hwan Won; Ji, Mi-Jung; Park, Hyun-Mee; Kong, Gu; Hur, Wooyoung |
| 2022-07 | Drug Discovery Using Evolutionary Similarities in Chemical Binding to Inhibit Patient-Derived Hepatocellular Carcinoma | Lim Jin Hong; Park, Keun wan; Choi Kyung Hwa; Kim Chan Wung; Lee Jae Ha; Weicker Raymond; PAN, CHEOL HO; Kim Seok-Mo; Park Ki Cheong |
| 2022-04 | Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery | Shim, Man Kyu; Yang, Suah; Sun, In-Cheol; Kim, Kwangmeyung |
| 2022-10 | Cancer therapy by antibody-targeted Cerenkov light and metabolism-selective photosensitization | Jo, chihoon; Ahn, Heesu; Kim, ji hwan; Lee, Yong Jin; Kim, Jung Young; Lee, Kyo Chul; Kang, Chi Soo; Kim, Sehoon |
| 2023-03 | A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation | West, Jeffrey; Adler, Fred; Gallaher, Jill; Strobl, Maximilian; Brady-Nicholls, Renee; Brown, Joel; Roberson-Tessi, Mark; Kim, Eunjung; Noble, Robert; Viossat, Yannick; Basanta, David; Anderson, Alexander RA |
| 2021-12-01 | Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma | Kwon, Minsu; Nam, Gi-Hoon; Jung, Hanul; Kim, Seong A.; Kim, Seohyun; Choi, Yeonju; Lee, Yoon Se; Cho, Hyo Jung; Kim, In-San |
| 2021-08 | Anticoagulation therapy promotes the tumor immune-microenvironment and potentiates the efficacy of immunotherapy by alleviating hypoxia | Choi, Jeong Uk; Lee, Na Kyeong; Seo, Hyungseok; Chung, Seung Woo; Al-Hilal, Taslim A.; Park, Seong Jin; Kweon, Seho; Min, Nuri; Kim, Sang Kyoon; Ahn, Seohyun; Kim, Uk-Il; Park, Jin Woo; Kang, Chang-Yuil; Kim, In-San; Kim, Sang Yoon; Kim, Kyungjin; Byun, Youngro |
| 2021-05 | Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity | Yang, Suah; Shim, Man Kyu; Kim, Woo Jun; Choi, Jiwoong; Nam, Gi-Hoon; Kim, Jeongrae; Kim, Jinseong; Moon, Yujeong; Kim, Han Young; Park, Jooho; Park, Yoon; Kim, In-San; Ryu, Ju Hee; Kim, Kwangmeyung |
| 2021-10 | Caspase-cleavable peptide-doxorubicin conjugate in combination with CD47-antagonizing nanocage therapeutics for immune-mediated elimination of colorectal cancer | Lee, Na Kyeong; Choi, Jeong Uk; Kim, Ha Rin; Chung, Seung Woo; Ko, Yoon Gun; Cho, Young Seok; Park, Seong Jin; Lee, Eun Jung; Kim, Sang Yoon; Kim, In-San; Byun, Youngro |
